VivoSeq
Other

Compulsive Behaviors

4

Pipeline Programs

0

Active Trials

3

Companies Involved

Compulsive behaviors is an early-stage landscape with 4 programs across 3 companies. The most active players are GSK, Alnylam Pharmaceuticals, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections.

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

50/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Trial Status

2

clinical trials

Completed1 · 50%
Withdrawn1 · 50%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)